Streetbeat News

TCBP

TC Biopharm (Holdings) Plc

https://www.tcbiopharm.com

Industry

Biotechnology

TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an unmodified cell therapy used in the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat COVID-19. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.

Open

0.78

Mkt cap

188K

Volume

27M

High

0.96

P/E Ratio

N/A

52-wk high

138.00

Low

0.56

Div yield

N/A

52-wk low

0.56

TC Biopharm's stock price has risen following the announcement that the FDA has cleared the Phase 1B Investigational New Drug (IND) application for TCB-008, a treatment for Acute Myeloid Leukemia.

Portfolio Pulse from Benzinga Newsdesk

November 27, 2023 | 2:47 pm

In Friday's after-market session, several healthcare stocks experienced significant movements. Mira Pharmaceuticals, TC BioPharm, Panbela Therapeutics, Estrella Immunopharma, Bio-Path Holdings, and MyMD Pharmaceuticals were among the gainers, with increases ranging from 7.14% to 9.2%. Conversely, Impel Pharmaceuticals, Avenue Therapeutics, Cyclacel Pharmaceuticals, Alaunos Therapeutics, Evoke Pharma, and Scholar Rock Holding were the losers, with their stock prices falling between 7.07% and 20.9%.

Portfolio Pulse from Benzinga Insights

November 24, 2023 | 9:31 pm

In Friday's pre-market session, several healthcare stocks experienced significant movements. Telesis Bio (TBIO) saw a 32.5% increase, while vTv Therapeutics (VTVT) faced a sharp 96.8% decline. Other notable gainers include Femasys (FEMY), Medigus (MDGS), TC BioPharm (TCBP), Assembly Biosciences (ASMB), and PaxMedica (PXMD). On the losing side, Impel Pharmaceuticals (IMPL), Aethlon Medical (AEMD), Ikena Oncology (IKNA), Biophytis (BPTS), and Heart Test Laboratories (HSCS) saw declines ranging from 10.56% to 31.96%.

Portfolio Pulse from Benzinga Insights

November 24, 2023 | 1:06 pm

In Wednesday's pre-market session, several healthcare stocks experienced significant movements. Heart Test Laboratories, PaxMedica, NeuroOne Medical Tech, Apollomics, TC BioPharm, and Curis saw their stocks rise by 23.9%, 23.24%, 14.68%, 14.18%, 13.99%, and 12.32% respectively. Conversely, UpHealth, Alterity Therapeutics, Nexalin Technology, SILO Pharma, Acutus Medical, and TRACON Pharma faced declines of 20.2%, 15.97%, 15.52%, 11.96%, 10.44%, and 10.05% respectively.

Portfolio Pulse from Benzinga Insights

November 22, 2023 | 1:06 pm

In Tuesday's pre-market session, several healthcare stocks experienced significant movements. SILO Pharma, TRACON Pharma, Fresh2 Group, Brainstorm Cell, TC BioPharm, and Connect Biopharma Hldgs saw their shares rise by 36.2%, 30.02%, 28.4%, 22.03%, 19.23%, and 17.47%, respectively. On the other hand, MorphoSys, Alzamend Neuro, Enzo Biochem, Cardio Diagnostics Hldgs, Sharps Technology, and Nemaura Medical saw their shares fall by 24.1%, 13.67%, 13.39%, 12.22%, 11.91%, and 10.17%, respectively. MorphoSys's drop is attributed to their Q3 earnings released 4 days ago.

Portfolio Pulse from Benzinga Insights

November 21, 2023 | 1:06 pm

Symbotic Inc. (NASDAQ:SYM) shares increased by approximately 22% in pre-market trading following the announcement of Q4 sales that surpassed analyst expectations. The company reported sales of $392 million against a consensus estimate of $306.9 million. Despite reporting a quarterly loss of 8 cents per share, this was an improvement from the 10 cents per share loss in the same period last year. Keybanc upgraded Symbotic's price target from $50 to $63. Other stocks also showed significant movement in pre-market trading, with various gainers and losers listed.

Portfolio Pulse from Lisa Levin

November 21, 2023 | 1:05 pm

In Monday's after-market session, several healthcare stocks experienced significant movements. NGM Biopharmaceuticals (NGM) saw an 11.5% increase, while TC BioPharm (TCBP) rose by 11.24%. Nemaura Medical (NMRD), Exagen (XGN), NanoVibronix (NAOV), and Allarity Therapeutics (ALLR) also posted gains. Conversely, Alzamend Neuro (ALZN) dropped by 19.4%, Gain Therapeutics (GANX) fell by 16.37%, Acutus Medical (AFIB) declined by 16.04%, AVITA Medical (RCEL) decreased by 11.2%, Vicarious Surgical (RBOT) went down by 10.67%, and Forte Biosciences (FBRX) fell by 9.77%.

Portfolio Pulse from Benzinga Insights

November 20, 2023 | 9:31 pm

During Tuesday's intraday session, several healthcare stocks experienced significant movements. Tenax Therapeutics (TENX) saw a massive increase of 319.0% to $0.65 with an exceptionally high trading volume. Tivic Health Systems (TIVC) rose by 68.89% following their Q3 earnings release. ZyVersa Therapeutics (ZVSA), INVO Bioscience (INVO), MSP Recovery (LIFW), and Tenon Medical (TNON) also saw gains ranging from 18.27% to 32.88%. On the downside, TC BioPharm (TCBP) plummeted by 90.0%, Aclaris Therapeutics (ACRS) dropped by 86.77%, and other stocks like Mainz Biomed (MYNZ), Verve Therapeutics (VERV), TRACON Pharma (TCON), and Alector (ALEC) experienced declines between 16.58% and 45.54%.

Portfolio Pulse from Benzinga Insights

November 14, 2023 | 5:31 pm

During Monday's intraday session, several healthcare stocks experienced significant movements. Tenax Therapeutics (TENX) saw a massive surge of 322.1%, while Tivic Health Systems (TIVC) and ZyVersa Therapeutics (ZVSA) also posted substantial gains. On the downside, TC BioPharm (TCBP), Aclaris Therapeutics (ACRS), and Mainz Biomed (MYNZ) faced steep declines. Verve Therapeutics (VERV), TRACON Pharma (TCON), and Alector (ALEC) also dropped notably, with recent Q3 earnings reports potentially influencing their stock performance.

Portfolio Pulse from Benzinga Insights

November 13, 2023 | 5:31 pm

In Monday's pre-market session, several healthcare stocks showed significant movement. Tivic Health Systems (TIVC) saw a 116.8% increase, while SenesTech (SNES) rose by 65.78%. ZyVersa Therapeutics (ZVSA) and Cingulate (CING) also experienced gains. On the downside, TC BioPharm (TCBP) dropped by 89.2%, Aclaris Therapeutics (ACRS) fell by 85.6%, and Verve Therapeutics (VERV) declined by 31.53%. Other stocks such as TRACON Pharma (TCON), Monopar Therapeutics (MNPR), and Singular Genomics Systems (OMIC) also saw decreases. Earnings reports seem to be a driving factor for many of these movements.

Portfolio Pulse from Benzinga Insights

November 13, 2023 | 1:06 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.